Literature DB >> 26310813

Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor-α mRNA via decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR.

Zhijie Zhu1,2, Yang Zhao1,2, Junbo Li3, Li Tao1,2, Peiliang Shi3, Zhonghong Wei1,2, Xiaobo Sheng1,2, Dandan Shen1,2, Zhaoguo Liu1,2, Liang Zhou1,2, Chao Tian1,2, Fangtian Fan1,2, Cunsi Shen1,2, Pingting Zhu1,2, Aiyun Wang1,2,4, Wenxing Chen1,2,4, Qingshun Zhao3, Yin Lu5,6,7.   

Abstract

Cryptotanshinone (CT), one major lipophilic component isolated from Salvia miltiorrhiza Bunge, has shown to possess chemopreventive properties against various types of cancer cells. In this study, CT was shown to be a potent anti-angiogenic agent in zebrafish, and mouse models and could limit tumor growth by inhibiting tumor angiogenesis. We further found that CT could inhibit the proliferation, migration, angiogenic sprouting, and tube formation of HUVECs. In addition, we demonstrated that CT could lower the level of TNF-α due to the destabilization of TNF-α mRNA, which associated with regulating 3'-untranslated region (3'-UTR) of TNF-α and preventing the translocation of RNA binding protein, HuR, from the nucleus to the cytoplasm. Moreover, the underlying mechanism responsible for the regulation in angiogenesis by CT was partially related to the suppression of NF-κB, and STAT3 activity. Based on the abilities of CT in targeting tumor cells, inhibiting angiogenesis, and destroying tumor vasculature, CT is worthy of further investigation for preventive, and therapeutic purposes in cancer.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  HuR; angiogenesis; cryptotanshinone; mRNA stability; tumor necrosis factor-α

Mesh:

Substances:

Year:  2015        PMID: 26310813     DOI: 10.1002/mc.22383

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  9 in total

1.  miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R.

Authors:  Lili Ren; Yong Li; Qun Zhao; Liqiao Fan; Bibo Tan; Aimin Zang; Hua Yang
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

Review 2.  Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).

Authors:  Christopher W Schultz; Ranjan Preet; Teena Dhir; Dan A Dixon; Jonathan R Brody
Journal:  Wiley Interdiscip Rev RNA       Date:  2020-01-23       Impact factor: 9.957

3.  Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer.

Authors:  Lingyi Shi; Hailun Zheng; Wanle Hu; Bin Zhou; Xuanxuan Dai; Yi Zhang; Zhiguo Liu; Xiaoping Wu; Chengguang Zhao; Guang Liang
Journal:  Onco Targets Ther       Date:  2017-03-23       Impact factor: 4.147

4.  Cryptotanshinone hinders renal fibrosis and epithelial transdifferentiation in obstructive nephropathy by inhibiting TGF-β1/Smad3/integrin β1 signal.

Authors:  Wei Wang; Pang-Hu Zhou; Chao-Zhao Liang; Jie Zhang; Wei Hu; Chang-Geng Xu; Xiang-Jun Zhou
Journal:  Oncotarget       Date:  2017-12-27

Review 5.  Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Sha Li; Yibin Feng
Journal:  Integr Cancer Ther       Date:  2018-05-28       Impact factor: 3.279

Review 6.  Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.

Authors:  Lorena Avila-Carrasco; Pedro Majano; José Antonio Sánchez-Toméro; Rafael Selgas; Manuel López-Cabrera; Abelardo Aguilera; Guadalupe González Mateo
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

Review 7.  Challenges and strategies in progress of drug delivery system for traditional Chinese medicine Salviae Miltiorrhizae Radix et Rhizoma (Danshen).

Authors:  Ruo-Ning Wang; Hua-Cong Zhao; Jian-Yu Huang; Hong-Lan Wang; Jun-Song Li; Yin Lu; Liu-Qing Di
Journal:  Chin Herb Med       Date:  2020-11-14

8.  Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.

Authors:  Rubin Cheng; Yilan Huang; Yun Fang; Qirui Wang; Meixiu Yan; Yuqing Ge
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

Review 9.  The Anticancer Properties of Tanshinones and the Pharmacological Effects of Their Active Ingredients.

Authors:  Li Fu; Bing Han; Yang Zhou; Jie Ren; Wenzhi Cao; Gopal Patel; Guoyin Kai; Jun Zhang
Journal:  Front Pharmacol       Date:  2020-03-19       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.